新兴制造商参与COVID-19疫苗研发与供应
通过在线检索、网络成员直接沟通和内部调查,评估发展中国家疫苗制造商网络成员参与COVID-19疫苗研发及生产、灌装和分发的能力。目前19个网络成员参与COVID-19疫苗研发,使用六种主要技术平台;利用现有生产、灌装和分发能力可支持COVID-19疫苗的有效推出,同时维持现有免疫规划疫苗的供应安全。
要点
- 19个网络成员参与COVID-19疫苗研发,使用六种主要技术平台。
- 近三分之一网络成员有WHO预认证疫苗,符合国际法规和跨境分发机制。
核心结论
- 利用现有生产、灌装和分发能力可支持COVID-19疫苗的有效推出,同时维持现有免疫规划疫苗的供应安全。
研究设计与样本
- 通过在线检索、与网络成员直接沟通及内部调查,评估发展中国家疫苗制造商网络成员参与COVID-19疫苗研发及生产、灌装和分发的能力。
主要发现
- 目前19个网络成员参与COVID-19疫苗研发,使用六种主要技术平台。
- 近三分之一网络成员有WHO预认证疫苗,符合国际法规和跨境分发机制。
临床怎么用
- 可依托现有生产、灌装和分发能力支持COVID-19疫苗推出,并维持现有免疫规划疫苗供应安全。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The World Health Organization declared the COVID-19 disease as a pandemic requiring a rapid response. Through online search, direct communication with network members and an internal survey, engagements of developing countries' vaccine manufacturers' network members in the research and development of COVID-19 vaccines and their capacities in the manufacturing, fill-finish and distribution of vaccines were assessed. Currently, 19 network members engaged in research and development of COVID-19 vaccines, using six principal technology platforms. In addition, an internal survey showed that the number of vaccines supplied collectively by 37 members, in 2018-19, was about 3.5 billion doses annually. Almost a third of network members having vaccines prequalified by the World Health Organization comply with international regulations and mechanisms to distribute vaccines across borders. The use of existing manufacturing, fill-finish and distribution capabilities can support an efficient roll-out of vaccines against COVID-19, while maintaining supply security of existing vaccines for on-going immunization programmes.
引用
- Pagliusi S, Jarrett S, Hayman B, et al. Emerging manufacturers engagements in the COVID -19 vaccine research, development and supply. Vaccine. 2020. PMID: 32600908. doi:10.1016/j.vaccine.2020.06.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。